# Immix Biopharma Reports $340.9 Million in Cash, Cash Equivalents and Marketable Securities

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/56042
Published: 2026-11-12T23:33:28.000Z
Updated: 2026-11-12T23:33:28.000Z
Section: Business

> The company expects the balance at quarter-end to fund operations into mid-2028. Third-quarter operating expenses were $15.9 million.

Immix Biopharma held $340.9 million in cash, cash equivalents and marketable securities as of Sept. 30, 2026, and expects that balance to fund operations into mid-2028.

Operating expenses totaled $15.9 million for the three months ended Sept. 30, the third quarter of 2026.